VIVJOA provided nearly 2 years of sustained efficacy against RVVC in a long-term extension of Phase 3 studies DURHAM, N.C., Nov. 18, 2025 /PRNewswire/ -- Mycovia Pharmaceuticals, Inc. ("Mycovia") has announced the publication of long-term efficacy results from an extension study of the...
Hence then, the article about mycovia pharmaceuticals inc announces publication of 2 year vivjoa efficacy results from an extension of the violet phase 3 studies in women with recurrent vulvovaginal candidiasis rvvc in the journal of women s health was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Mycovia Pharmaceuticals, Inc. Announces Publication of 2-Year VIVJOA® Efficacy Results from an Extension of the VIOLET Phase 3 Studies in Women with Recurrent Vulvovaginal Candidiasis (RVVC) in the Journal of Women's Health )
Also on site :
- One Furious Judge Just Laid Out Exactly How Trump and Bondi Are Wrecking the DOJ
- ‘The Comeback’ Incited Public Confusion While Recreating 2023 Strikes Outside WB Lot: “Cars Were Honking”
- Gemini Space Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Gemini Space Station, Inc. - GEMI